SGI-1776 is a small molecule inhibitor primarily known for its role as a selective inhibitor of the protein kinase PIM (proviral integration site for Moloney murine leukemia virus). It has garnered attention in cancer research due to its potential to inhibit tumor growth by interfering with the signaling pathways that promote cell proliferation and survival. SGI-1776 exhibits characteristics typical of kinase inhibitors, including the ability to bind to the ATP-binding site of the PIM kinases, thereby blocking their activity. This compound has been studied for its effects on various cancer cell lines, demonstrating the ability to induce apoptosis and inhibit cell cycle progression. Additionally, SGI-1776 has shown promise in combination therapies, enhancing the efficacy of other anticancer agents. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity. As with many investigational drugs, ongoing research is essential to fully understand its pharmacokinetics, toxicity profile, and therapeutic potential in clinical settings.

SGI-1776

1173928-26-1: SGI-1776 is a small molecule inhibitor primarily known for its role as a selective inhibitor of the protein kinase PIM (proviral integration site for Moloney murine leukemia virus). It has garnered attention in cancer research due to its potential to inhibit tumor growth by interfering with the signaling pathways that promote cell proliferation and survival. SGI-1776 exhibits characteristics typical of kinase inhibitors, including the ability to bind to the ATP-binding site of the PIM kinases, thereby blocking their activity. This compound has been studied for its effects on various cancer cell lines, demonstrating the ability to induce apoptosis and inhibit cell cycle progression. Additionally, SGI-1776 has shown promise in combination therapies, enhancing the efficacy of other anticancer agents. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity. As with many investigational drugs, ongoing research is essential to fully understand its pharmacokinetics, toxicity profile, and therapeutic potential in clinical settings.

<p>Inhibits Pim kinase; anti-cancer agent</p>

CAS 1173928-26-1

SGI-1776

SGI 1776

Ref: 3D-FS103136